The cefoperazone-sulbactam combination. In vitro qualities including beta-lactamase stability, antimicrobial activity, and interpretive criteria for disk diffusion tests
- PMID: 2994461
- DOI: 10.1093/ajcp/84.4.496
The cefoperazone-sulbactam combination. In vitro qualities including beta-lactamase stability, antimicrobial activity, and interpretive criteria for disk diffusion tests
Abstract
Three concentrations of the penicillanic acid sulfone, sulbactam were tested in combination with cefoperazone against 632 recent clinical bacterial isolates. Cefoperazone was effective alone (less than or equal to 16 micrograms/mL) against 95% of Enterobacteriaceae and combined with 4 micrograms/mL sulbactam inhibited 99.5% of strains. This coverage of enteric bacilli was superior to timentin (99.1%), ceftazidime (98.2%), and tobramycin (90.9%). The minimum inhibitory concentrations (MICs) of cefoperazone-susceptible strains also were markedly decreased by sulbactam (overall MIC90s, 8.0 micrograms/mL for cefoperazone and 1.0 microgram/mL for cefoperazone and 4.0 micrograms/mL for sulbactam). Sulbactam also expanded the spectrum of cefoperazone against Acinetobacter species, some rare Pseudomonas species, and Bacteroides fragilis group species. Sulbactam had direct antimicrobial activity against the acinetobacters and Pseudomonas acidovorans, but the increased activity of cefoperazone-sulbactam against some other Pseudomonas species and anaerobes was attributed to beta-lactamase inhibition. The cefoperazone MICs against beta-lactamase producing Staphylococcus species also were lowered to the level of enzyme-deficient strains. Cefoperazone bactericidal activity was improved by 4.0 micrograms/mL sulbactam, and no antagonism was observed. beta-lactamase hydrolysis studies confirmed a slow hydrolysis of cefoperazone only by TEM beta-lactamases and a high-grade resistance to enzyme breakdown by sulbactam. Differential beta-lactamase affinity studies for cefoperazone and sulbactam showed potential efficacy and applications to plasmid-mediated TEM and OXA enzymes and only marginal effective sulbactam inhibition of Pseudomonas and Klebsiella species enzymes. Disk diffusion studies on 556 strains confirmed the applicability of the cefoperazone 75-micrograms disk to testing routine isolates other than enterococci and methicillin-resistant Staphylococcus aureus. The addition of 4.0 micrograms sulbactam/mL in a fixed concentration to dilution test systems and 15 micrograms sulbactam to the 75 micrograms cefoperazone disk were recommended for in vitro tests. Susceptibility and resistant interpretive criteria for the disk and dilution tests can be applied with confidence. Only 0.4% false-susceptibility errors and a 97.5% absolute interpretive agreement were achieved using the 75 micrograms cefoperazone/15 micrograms sulbactam disk.
Similar articles
-
In vitro antimicrobial activity of cefoperazone-sulbactam combinations against 554 clinical isolates including a review and beta-lactamase studies.Diagn Microbiol Infect Dis. 1985 Nov;3(6):489-99. doi: 10.1016/s0732-8893(85)80005-5. Diagn Microbiol Infect Dis. 1985. PMID: 2998694
-
Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).Diagn Microbiol Infect Dis. 1989 Nov-Dec;12(6):495-510. doi: 10.1016/0732-8893(89)90084-9. Diagn Microbiol Infect Dis. 1989. PMID: 2560422
-
Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.J Antimicrob Chemother. 1981 Sep;8 Suppl B:187-211. doi: 10.1093/jac/8.suppl_b.187. J Antimicrob Chemother. 1981. PMID: 19802985
-
beta-Lactamase inhibition and in vitro activity of sulbactam and sulbactam/cefoperazone.Clin Infect Dis. 1997 Mar;24(3):494-7. doi: 10.1093/clinids/24.3.494. Clin Infect Dis. 1997. PMID: 9114205 Review.
-
Cefoperazone/sulbactam: New composites against multiresistant gram negative bacteria?Infect Genet Evol. 2021 Mar;88:104707. doi: 10.1016/j.meegid.2021.104707. Epub 2021 Jan 5. Infect Genet Evol. 2021. PMID: 33418147 Review.
Cited by
-
Durlobactam, a Broad-Spectrum Serine β-lactamase Inhibitor, Restores Sulbactam Activity Against Acinetobacter Species.Clin Infect Dis. 2023 May 1;76(Suppl 2):S194-S201. doi: 10.1093/cid/ciad095. Clin Infect Dis. 2023. PMID: 37125470 Free PMC article.
-
In vitro activities of ampicillin-sulbactam and cefoperazone-sulbactam against oxacillin-susceptible and oxacillin-resistant staphylococci.Antimicrob Agents Chemother. 1990 Sep;34(9):1830-2. doi: 10.1128/AAC.34.9.1830. Antimicrob Agents Chemother. 1990. PMID: 2285302 Free PMC article.
-
In vitro antimicrobial spectrum, occurrence of synergy, and recommendations for dilution susceptibility testing concentrations of the cefoperazone-sulbactam combination.J Clin Microbiol. 1987 Sep;25(9):1725-9. doi: 10.1128/jcm.25.9.1725-1729.1987. J Clin Microbiol. 1987. PMID: 3498740 Free PMC article.
-
Error rates in cefoperazone and cefoperazone-sulbactam disk tests with Enterobacteriaceae and Pseudomonas aeruginosa.Eur J Clin Microbiol Infect Dis. 1992 Oct;11(10):926-30. doi: 10.1007/BF01962376. Eur J Clin Microbiol Infect Dis. 1992. PMID: 1486889
-
Criteria for disk susceptibility tests and quality control guidelines for the cefoperazone-sulbactam combination.J Clin Microbiol. 1988 Jan;26(1):13-7. doi: 10.1128/jcm.26.1.13-17.1988. J Clin Microbiol. 1988. PMID: 3343304 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources